A novel AGGF1-PDGFRβ fusion in pediatric T-cell acute lymphoblastic leukemia

With contemporary multiagent chemotherapy regimens, event-free survival rates for children with T-cell acute lymphoblastic leukemia (T-ALL) exceed 85%, paralleling those observed in B-lineage acute lymphoblastic leukemia (B-ALL).[1][1] Outcomes for patients with relapsed and refractory T-ALL remain